BRIEF—GSK completes acquisition of Tesaro

UK pharma major GlaxoSmithKline today announced that it has successfully completed the acquisition of Tesaro, an oncology-focused company based in Waltham, Massachusetts, for an aggregate cash consideration of approximately $5.1 billion (£4.0 billion), marking a major return into cancer therapeutics for the company.

The transaction, which was announced on December 3, 2018, significantly strengthens GSK’s pharmaceutical business, accelerating the build of GSK’s pipeline and commercial capability in oncology.

Tesaro is a commercial-stage biopharmaceutical company, with a major marketed product, Zejula (niraparib), an oral poly ADP ribose polymerase (PARP) inhibitor currently approved for use in ovarian cancer.

Zejula is currently approved in the USA and Europe as a treatment for adult patients with recurrent ovarian cancer who are in response to platinum-based chemotherapy, regardless of BRCA mutation or biomarker status.